Inovio Pharmaceuticals, Inc. (INO): Price and Financial Metrics
INO Stock Summary
- INO's price/sales ratio is 244.86; that's higher than the P/S ratio of 97.91% of US stocks.
- With a year-over-year growth in debt of -60.76%, Inovio Pharmaceuticals Inc's debt growth rate surpasses only 5.15% of about US stocks.
- As for revenue growth, note that INO's revenue has grown 80.24% over the past 12 months; that beats the revenue growth of 93.63% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Inovio Pharmaceuticals Inc are CMRX, SRRK, GLYC, NXTC, and ALPN.
- Visit INO's SEC page to see the company's official filings. To visit the company's web site, go to www.inovio.com.
INO Stock Price Chart Interactive Chart >
INO Price/Volume Stats
| Current price | $8.74 | 52-week high | $33.79 |
| Prev. close | $9.01 | 52-week low | $7.54 |
| Day low | $8.53 | Volume | 8,920,100 |
| Day high | $8.97 | Avg. volume | 14,471,971 |
| 50-day MA | $10.63 | Dividend yield | N/A |
| 200-day MA | $12.94 | Market Cap | 1.82B |
Inovio Pharmaceuticals, Inc. (INO) Company Bio
Inovio Pharmaceuticals is a clinical stage biopharmaceutical company, developing active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company was founded in 1979 and is based in Plymouth Meeting, Pennsylvania.
Latest INO News From Around the Web
Below are the latest news stories about Inovio Pharmaceuticals Inc that investors may wish to consider to help them evaluate INO as an investment opportunity.
Lifshitz Law Firm, P.C. Announces Investigations of Inovio Pharmaceuticals, Inc. (NasdaqGS: INO), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA)NEW YORK, April 16, 2021 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NasdaqGS: INO) Lifshitz Law Firm, P.C. announces that on February 16, 2021, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss a putative class action complaint alleging that INO and certain officers made misleading statements about the Company’s development of a purported vaccine for the novel coronavirus, artificially inflating the Company’s share price and resulting in significant investor losses. Specifically, the Complaint alleges that Defendants capitalized on widespread COVID-19 fears by falsely claiming that Inovio had developed a vaccine for COVID-19. Plaintiffs alleged that Inovio’s stock price rose significantly in response to this disclosure, but plummeted whe... |
INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of ConcernINOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focusing on the human immune responses induced by INOVIO's DNA vaccine candidate for COVID-19, INO-4800, against variants of concern. The results showed that INO-4800 induced a robust T cell response against all spike protein variants tested, which the company believes will be key in providing protection against SARS-CoV-2 variants, in addition to providing similar levels of neutralizing activity against both the UK and Brazilian variants as those against the original strain. The study, entitled "INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity A... |
Inovio Is Still Working On A Midstage Covid Vaccine Test — Is It A Buy?Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news. |
Do Options Traders Know Something About Inovio (INO) Stock We Don't?Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately. |
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INOFormer Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO). |
INO Price Returns
| 1-mo | -13.55% |
| 3-mo | N/A |
| 6-mo | -20.55% |
| 1-year | 5.81% |
| 3-year | 88.77% |
| 5-year | -12.60% |
| YTD | -1.24% |
| 2020 | 168.18% |
| 2019 | -17.50% |
| 2018 | -3.15% |
| 2017 | -40.49% |
| 2016 | 3.27% |
Continue Researching INO
Want to see what other sources are saying about Inovio Pharmaceuticals Inc's financials and stock price? Try the links below:Inovio Pharmaceuticals Inc (INO) Stock Price | Nasdaq
Inovio Pharmaceuticals Inc (INO) Stock Quote, History and News - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...